Clinical Trial Update: An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer

View source ↗

Summary

An indirect treatment comparison evaluates the effectiveness of ribociclib plus non-steroidal aromatase inhibitors versus tamoxifen for adjuvant therapy in prem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Letrozole (letrozole)
• Ribociclib (ribociclib)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: COMPLETED